ReviewCell division2025
Molecular pathology of microRNA-339 during tumor progression.
Review in Cell division, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ruanjian Sanjie Formula Affects Metastasis of Lung Cancer by Regulating miR-182-5p/EPAS1/EMT Axis.Chinese journal of integrative medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer, as one of the main causes of human deaths, has an adverse effect on the quality of life in cancer patients. Despite many advances in diagnostic and therapeutic methods, there is still a poor prognosis in cancer patients that can be associated with the late tumor diagnosis. Therefore, investigating the molecular pathology of cancer can help to introduce early diagnostic markers. MicroRNAs (miRNAs) have key roles in regulation of cell proliferation, migration, and apoptosis. Deregulations of miRNAs have been widely reported in various cancers. Regarding the high stability of miRNAs in body fluids, they can be used as the non-invasive diagnostic markers in tumor screening programs and early detection. Considering the aberrant expression of miR-339 in a wide range of tumors, we discussed the role of miR-339 during tumor progressions. MiR-339 mainly functions as a tumor suppressor by the modulation of apoptosis, transcription factors, and signaling pathways. This review can be an effective step towards suggesting miR-339 as a therapeutic target and diagnostic marker in cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.